Qvanteq AG is a venture leader China
Arik Zucker is one of the winners of the venture leader China program.
Qvanteq AG chosen as a 2015 Red Herring Europe Winner
Amsterdam, Netherlands – Red Herring announced its Red Herring Europe award winners today, recognizing Europe’s leading private companies and celebrating these startups’ innovations and technologies across their respective industries. Continue reading
The Swiss coronary stent company Qvanteq AG enrolled first patient in the QUEST I clinical study
Qvanteq AG today announced that it has enrolled the first patient in the First in Man (FiM) clinical study QUEST I, this is following earlier regulatory approval from the Dutch and Swiss authorities. The aim of the QUEST I study is to assess feasibility and safety of the Qstent, a bioactive, coating-free coronary stent. The Qstent has shown excellent in-growth and low thrombogenicity in pre-clinical studies. Continue reading